Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanse Medical Expense Reaches ¥3.4 Trillion; Growth Slows To Below 2 Percent

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare released medical expenses accounting records for FY2008. The combination of national health insurance expenses and medical fees is ¥3.41 trillion, another record number for six years in a row. According to the ministry, the annual growth of the expense in 2008 slowed down to 1.9 percent, compared to a 3.1 percent increase in FY2007. The slow down in growth is a result of a government medical reimbursement change in 2008 that encouraged generic drug substitution. Medical expenses among seniors over 70 years of age accounted for 43.5 percent or ¥1.48 trillion, an increase of 2.1 percent or ¥310 billion. Medical expense per capita is ¥267,000, increased by 1.9 percent or ¥5,000 compared to 2007. (Click here for more - Japanese language

You may also be interested in...



P&G Boosts Guidance Again Despite Dipping 'Consumption Levels' Expected Through June

On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.

P&G’s Moeller Tackles ‘Volatile’ Markets'

Moeller, CFO since 2009, will retain vice chairman and COO posts and continue heading P&G’s enterprise markets, the firm’s smaller markets,

Merck & Co. Pushes Back On Modest Projections For Verquvo

Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel